Duesseldorf

• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
• Trial on efficacy and safety of vaccination of newly diagnosed glioblastoma patients with the patient's own immune cells. Ended recruitment
  2024-514820-18-00 4 2018-03-07 newly diagnosed glioblastoma
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• L19TNF plus doxorubicin in patients with STS Ended recruitment
  2024-512789-32-00 5 2017-10-09 Unresectable or metastatic soft tissue sarcoma
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit … Ended recruitment
  2024-513509-30-00 5 2016-01-11 Progressive or recurrent germ cell tumor (measurable or non-measurable
• Study to Evaluate Imetelstat (GRN163L) in Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Ended recruitment
  2024-511348-25-00 10 2015-12-11 Myelodysplastic syndromes (MDS)
• Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA … Ended recruitment
  2024-515619-23-00 4 2015-06-29 polycythemia vera
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL) Halted
  2023-505840-20-00 9 2024-08-16 B-Cell Acute Lymphoblastic Leukaemia
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2) Halted
  2023-507820-22-00 3 2024-05-22 Progressive Multiple Sclerosis (PMS)
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1) Halted
  2023-503823-24-01 3 2024-04-15 Systemic Sclerosis
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Halted
  2022-500783-35-00 5 2022-12-06 Acute Myeloid Leukemia
• Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis Ended
  2024-517623-39-00 5 2025-08-25 inclusion body myositis
• A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of … Ended
  2024-517814-13-00 4 2025-04-30 Moderate to Severe Atopic Dermatitis
• A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment Ended
  2024-515410-41-00 9 2025-04-01 BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended
  2024-510972-19-00 4 2025-03-13 Primary mediastinal large B-cell lymphoma (PMBCL)
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511360-87-00 5 2024-10-02 hidradenitis suppurativa (HS)
• Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Ended
  2023-506866-30-00 4 2024-08-19 HER2 positive or HER2-low metastatic breast cancer
• Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia Ended
  2023-508819-23-00 3 2024-07-24 Primary immune thrombocytopenia (ITP)
• A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas … Ended
  2023-509947-29-00 4 2024-07-18 Anemia in patients with very low, low or intermediate risk myelodyspla

Showing 289–312 of 382 trials